price,drug,ticker,date_text,end_date,stage
10.98,Aironite - INDIE,SVRA,,03/11/2018,Phase 2
11.26,SYNB1020,SYBX,"March 11-14, 2018;",03/11/2018,Phase 1
8.83,AEB1102,AGLE,"March 12, 2018;",03/12/2018,Phase 1/2
5.20,Galinpepimut-S,SLS,,03/19/2018,Phase 2
34.07,UCART19 - CALM,CLLS,,03/21/2018,Phase 1
34.07,UCART19 (PALL),CLLS,,03/21/2018,Phase 1
11.24,Mirvetuximab soravtansine - FORWARD II,IMGN,"March 24-27, 2018;",03/24/2018,Phase 1b
191.10,BLINCYTO,AMGN,,03/29/2018,PDUFA
1.75,NasoVAX,ALT,1Q 2018;,03/31/2018,Phase 1/2
116.87,ANB020,ANAB,March 2018;,03/31/2018,Phase 2a
2.64,Sollpura - RESULT,ANTH,March 2018;,03/31/2018,Phase 3
47.80,AM0010 (PEG-IL-10),ARMO,Early 2018;,03/31/2018,Phase 3
42.27,Etrasimod,ARNA,1Q 2018;,03/31/2018,Phase 2
30.50,Rimegepant,BHVN,1Q 2018;,03/31/2018,Phase 3
1.81,Prexigebersen,BPTH,Early 2018;,03/31/2018,Phase 2
7.95,Rezafungin (CD101) IV - STRIVE,CDTX,1Q 2018;,03/31/2018,Phase 2
0.27,Keyzilen (AM-101) - TACTT3,EARS,1Q 2018;,03/31/2018,Phase 3
75.26,Bempedoic Acid - 1002-039,ESPR,March 2018;,03/31/2018,Phase 2
5.07,FLX-787 (Aust),FLKS,March 2018;,03/31/2018,Phase 2
2.80,Imetelstat - IMbarkStudy,GERN,1Q 2018;,03/31/2018,Phase 2
80.72,GS-5745,GILD,1Q 2018;,03/31/2018,Phase 3
80.72,GS-9674,GILD,1Q 2018;,03/31/2018,Phase 2
80.72,Entospletinib,GILD,1Q 2018;,03/31/2018,Phase 2
117.04,Epidiolex,GWPH,1Q 2018;,03/31/2018,Phase 3
117.04,GWP42006 (CBDV),GWPH,1Q 2018;,03/31/2018,Phase 2
11.24,Mirvetuximab soravtansine - FORWARD I,IMGN,1Q 2018;,03/31/2018,Phase 3
11.45,MB-102,MBIO,Early 2018;,03/31/2018,Phase 1
11.45,MB-101,MBIO,Early 2018;,03/31/2018,Phase 1
0.69,OPRX-106,PLX,March 2018;,03/31/2018,Phase 2
23.08,PTG-100,PTGX,Early 2018;,03/31/2018,Phase 2b
4.12,PTI-428 + Kalydeco,PTI,1Q 2018;,03/31/2018,Phase 1
22.15,Bardoxolone methyl - LARIAT,RETA,1Q 2018;,03/31/2018,Phase 2
4.30,RXI-109-1501,RXII,1Q 2018;,03/31/2018,Phase 1/2
5.20,NeuVax in combination with Herceptin,SLS,1Q 2018;,03/31/2018,Phase 2b
2.14,Topsalysin (PRX302),SPHS,Late-1Q 2018;,03/31/2018,Phase 2
68.12,Niraparib - (QUADRA trial),TSRO,1Q 2018;,03/31/2018,Phase 2
6.42,TTP399,VTVT,Early 2018;,03/31/2018,Phase 1/2
55.14,Keytruda,MRK,,04/03/2018,PDUFA priority review
62.12,Rucaparib ARIEL3,CLVS,,04/06/2018,PDUFA priority review
31.90,EXPAREL,PCRX,,04/06/2018,PDUFA
82.76,AIN457 (Cosentyx),NVS,"April 7-10, 2018;",04/09/2018,Phase 3
9.75,Pegylated Interferon Lambda (LIMT HDV),EIGR,EASL 2018.;,04/11/2018,Phase 2
11.07,SEL-212,SELB,1H April 2018;,04/13/2018,Phase 2
9.75,Lonafarnib - LOWR HDV,EIGR,,04/14/2018,Phase 2
5.14,GR-MD-02,GALT,,04/14/2018,Phase 2b
67.92,CM-214 – Opdivo + Yervoy,BMY,,04/16/2018,PDUFA priority review
53.80,KRN23 Burosumab,RARE,,04/17/2018,PDUFA priority review
4.50,Fostamatinib,RIGL,,04/17/2018,PDUFA
117.04,Epidiolex,GWPH,,04/19/2018,PDUFA priority review
78.60,ARGX-113,ARGX,"AAN Meeting (April 21-27, 2018);",04/21/2018,Phase 2
12.51,MN-166,MNOV,,04/27/2018,Phase 2
92.43,Elagolix,NBIX,,04/27/2018,PDUFA priority review
16.45,Lubiprostone,MNK,,04/28/2018,PDUFA
2.69,OpRegen,BTX,,04/29/2018,Phase 1/2
191.10,KYPROLIS (ENDEAVOR),AMGN,,04/30/2018,PDUFA
62.12,Rucaparib - TRITON2,CLVS,Fall 2018;,04/30/2018,Phase 2
17.20,EG-1962,EDGE,April 2018;,04/30/2018,Phase 3
16.86,Selinexor - STORM,KPTI,April 2018;,04/30/2018,Phase 2b
5.89,Lefamulin - LEAP 2,NBRV,Spring 2018;,04/30/2018,Phase 3
82.76,Kymriah (CTL019 )- JULIET,NVS,,04/30/2018,PDUFA priority review
8.10,Azedra,PGNX,,04/30/2018,PDUFA priority review
4.50,Fostamatinib,RIGL,April 2018;,04/30/2018,Phase 2
16.60,RPL554,VRNA,Early 2Q 2018;,04/30/2018,Phase 2b
6.42,Azeliragon - STEADFAST,VTVT,April 2018;,04/30/2018,Phase 3
57.19,ADCETRIS  in combination with chemotherapy ECHELON-1,SGEN,,05/01/2018,PDUFA priority review
38.43,Andexanet alfa,PTLA,,05/04/2018,PDUFA
1.58,LPCN 1021,LPCN,,05/08/2018,PDUFA
19.44,Volanesorsen - APPROACH,AKCA,"Adcom May 10; PDUFA August 30, 2018.;",05/10/2018,PDUFA
15.38,Plenvu (NER1006),VRX,,05/13/2018,PDUFA
33.79,Tagrisso - FLAURA,AZN,Estimate mid-2Q 2018;,05/15/2018,PDUFA priority review
191.10,Erenumab,AMGN,,05/17/2018,PDUFA
82.76,Erenumab,NVS,,05/17/2018,PDUFA
29.62,Avatrombopag,DOVA,,05/21/2018,PDUFA priority review
133.80,DARZALEX (Daratumumab) - ALCYONE,JNJ,,05/21/2018,PDUFA priority review
83.81,Pegvaliase,BMRN,,05/25/2018,PDUFA priority review
10.50,Intravenous (IV) meloxicam,REPH,,05/26/2018,PDUFA
191.10,Prolia (denosumab),AMGN,,05/28/2018,PDUFA
5.47,Yuvvexy - TX-004HR,TXMD,,05/29/2018,PDUFA
75.26,Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046,ESPR,May 2018;,05/31/2018,Phase 3
75.26,Bempedoic acid (ETC-1002-040) - Clear Harmony,ESPR,May 2018;,05/31/2018,Phase 3
2.77,KIT-302,KTOV,,05/31/2018,PDUFA
82.76,Tafinlar (dabrafenib) and Mekinist (trametinib),NVS,Estimate mid-2Q 2018;,05/31/2018,PDUFA priority review
83.95,Enasidenib or ivosidenib with VIDAZA,AGIO,ASCO 2018;,06/01/2018,Phase 1/2
83.95,Ivosidenib,AGIO,ASCO 2018;,06/01/2018,Phase 1
231.95,bb2121,BLUE,ASCO 2018;,06/01/2018,Phase 1
17.55,SD-101 + Pembrolizumab,DVAX,ASCO 2018;,06/01/2018,Phase 1/2
2.07,IMO-2125 + ipilimumab - ILLUMINATE 301,IDRA,ASCO 2018 (Phase 1/2);,06/01/2018,Phase 3
68.12,Niraparib and Keytruda (TOPACIO),TSRO,ASCO 2018;,06/01/2018,Phase 1/2
36.77,Xeljanz,PFE,,06/13/2018,PDUFA
15.38,IDP-118,VRX,,06/18/2018,PDUFA
16.07,Furoscix,SCPH,,06/23/2018,PDUFA
11.44,Plazomicin,AKAO,,06/25/2018,PDUFA priority review
119.29,Rova-T (TRINITY),ABBV,2Q 2018;,06/30/2018,Phase 2
21.28,ATI-50002 - PK/safety,ACRS,1H 2018;,06/30/2018,Phase 2
21.28,ATI-50002 - open label,ACRS,1H 2018;,06/30/2018,Phase 2
27.69,GOCOVRI (amantadine),ADMS,2Q 2018;,06/30/2018,Phase 3
157.28,UBROGEPANT - ACHIEVE II (UBR-MD-02),AGN,1H 2018;,06/30/2018,Phase 3
157.28,Cariprazine,AGN,1H 2018;,06/30/2018,Phase 3
157.28,ATOGEPANT,AGN,1H 2018;,06/30/2018,Phase 2b
8.98,ALRN-6924,ALRN,1H 2018;,06/30/2018,Phase 2a
116.87,ANB020,ANAB,2Q 2018;,06/30/2018,Phase 2a
1.38,rocapuldencel-T (AGS-003) ADAPT Trial,ARGS,1H 2018;,06/30/2018,Phase 3
1.38,AGS-004 and vorinostat,ARGS,1H 2018;,06/30/2018,Phase 1
42.27,APD371,ARNA,2Q 2018;,06/30/2018,Phase 2
18.05,Binimetinib - COLUMBUS,ARRY,,06/30/2018,PDUFA
18.00,ASN100,ASNS,1H 2018;,06/30/2018,Phase 2
4.84,IV Tramadol,ATXI,2Q 2018;,06/30/2018,Phase 3
2.98,TIVO-3 - tivozanib,AVEO,2Q 2018;,06/30/2018,Phase 3
2.80,AXS-05 STRIDE-1,AXSM,2Q 2018;,06/30/2018,Phase 3
33.79,Selumetinib - ASTRA,AZN,1H 2018;,06/30/2018,Phase 3
33.79,Lynparza,AZN,1H 2018;,06/30/2018,Phase 3
33.79,Durvalumab +/- tremelimumab (MYSTIC),AZN,1H 2018;,06/30/2018,Phase 3
33.79,Durvalumab +/- tremelimumab (KESTREL),AZN,1H 2018;,06/30/2018,Phase 3
33.79,Durvalumab +/- tremelimumab (EAGLE),AZN,1H 2018;,06/30/2018,Phase 3
33.79,Durvalumab +/- tremelimumab (ARCTIC),AZN,1H 2018;,06/30/2018,Phase 3
67.92,CM-511 – Opdivo + Yervoy,BMY,1H 2018;,06/30/2018,Phase 3
67.92,CM-331– Opdivo,BMY,1H 2018;,06/30/2018,Phase 3
67.92,CM-227 – Opdivo + Yervoy,BMY,1H 2018;,06/30/2018,Phase 3
67.92,CM-548 - Opdivo+SOC,BMY,1H 2018;,06/30/2018,Phase 2
36.24,AT342 - VALENS,BOLD,2Q 2018;,06/30/2018,Phase 1/2
36.24,AT132 - ASPIRO,BOLD,2Q 2018;,06/30/2018,Phase 1/2
92.56,REVLIMID - AUGMENT NHL-007,CELG,1H 2018;,06/30/2018,Phase 3
4.75,CK-101,CKPT,1H 2018;,06/30/2018,Phase 1/2
2.82,Glembatumumab vedotin,CLDX,2Q 2018;,06/30/2018,Phase 2b
13.00,Suprachoroidal CLS-TA - TYBEE,CLSD,2Q 2018;,06/30/2018,Phase 2
13.00,Suprachoroidal CLS-TA - HULK,CLSD,2Q 2018;,06/30/2018,Phase 1/2
17.05,Palovarotene,CMTA,2Q 2018;,06/30/2018,Phase 2
7.27,Emricasan,CNAT,2Q 2018;,06/30/2018,Phase 2b
12.01,Corplex Donepezil,CORI,1H 2018;,06/30/2018,Phase 1
3.23,Firdapse,CPRX,1H 2018;,06/30/2018,Phase 3
0.32,Neutrolin - LOCK-IT 100,CRMD,2Q 2018;,06/30/2018,Phase 3
4.01,PIXUVRI - PIX306 Trial,CTIC,2Q 2018;,06/30/2018,Phase 3
4.01,Pacritinib - PAC203,CTIC,2Q 2018;,06/30/2018,Phase 3
8.30,CK-2127107,CYTK,2Q 2018;,06/30/2018,Phase 2
9.43,Glycopyrronium tosylate (DRM04),DERM,,06/30/2018,Phase 3
20.37,DNL201,DNLI,1H 2018;,06/30/2018,Phase 1
24.53,IMblaze370 - cobimetinib and atezolizumab,EXEL,1H 2018;,06/30/2018,Phase 3
4.95,CEVA101,FBIO,1H 2018;,06/30/2018,Phase 2
4.95,Pepvax vaccine,FBIO,1H 2018;,06/30/2018,Phase 2
26.73,Zilretta - FX006,FLXN,2Q 2018;,06/30/2018,Phase 2
14.91,ATB200,FOLD,2Q 2018;,06/30/2018,Phase 1/2
7.71,Gemcabene - INDIGO-1,GEMP,2Q 2018;,06/30/2018,Phase 2b
80.72,Selonsertib (GS-4997),GILD,2Q 2018;,06/30/2018,Phase 2
80.72,GS-9674,GILD,2Q 2018;,06/30/2018,Phase 2
6.38,Aramchol - ARREST,GLMD,2Q 2018;,06/30/2018,Phase 2b
103.18,GLPG2737 - PELICAN,GLPG,1H 2018;,06/30/2018,Phase 2
103.18,Filgotinib - TORTUGA,GLPG,2Q 2018;,06/30/2018,Phase 2
103.18,Filgotinib - EQUATOR,GLPG,2Q 2018;,06/30/2018,Phase 2
34.23,G1T38 plus Faslodex,GTHX,2Q 2018;,06/30/2018,Phase 1b
22.75,HTX-011,HRTX,1H 2018;,06/30/2018,Phase 3
2.07,IMO-8400,IDRA,2Q 2018;,06/30/2018,Phase 2
1.83,Eftilagimod alpha and Keytruda,IMMP,1H 2018;,06/30/2018,Phase 1
94.23,Epacadostat with Keytruda - ECHO-301,INCY,1H 2018;,06/30/2018,Phase 3
94.23,Ruxolitinib - REACH 1,INCY,1H 2018;,06/30/2018,Phase 3
2.55,IPI-549 + Nivolumab,INFI,2Q 2018;,06/30/2018,Phase 1
24.96,JTX-2011,JNCE,2Q 2018;,06/30/2018,Phase 1/2
133.80,Esketamine,JNJ,2018;,06/30/2018,Phase 3
6.80,KP415,KMPH,2Q 2018;,06/30/2018,Phase 3
22.90,Tipifarnib,KURA,1H 2018;,06/30/2018,Phase 2
128.98,LOXO-292,LOXO,1H 2018;,06/30/2018,Phase 1
11.58,MM-141 - CARRIE,MACK,1H 2018;,06/30/2018,Phase 2
4.35,NexoBrid,MDWD,1H 2018;,06/30/2018,Phase 3
2.16,ME-401,MEIP,2Q 2018;,06/30/2018,Phase 1
2.16,ME-344,MEIP,2Q 2018;,06/30/2018,Phase 1
2.16,Pracinostat in combination with Vidaza,MEIP,2Q 2018;,06/30/2018,Phase 2
6.73,MSC-100-IV,MESO,2Q 2018;,06/30/2018,Phase 3
30.58,Margetuximab in combination with pembrolizumab,MGNX,1H 2018;,06/30/2018,Phase 2
33.00,Serlopitant,MNLO,2Q 2018;,06/30/2018,Phase 2
55.14,(MK-3475-189/KEYNOTE-189),MRK,"1H 2018 (est, only);",06/30/2018,Phase 3
1.04,MAT2501,MTNB,2Q 2018;,06/30/2018,Phase 2
92.43,NBI-74788,NBIX,1H 2018;,06/30/2018,Phase 2a
7.85,Indoximod + gemcitabine and nab-paclitaxel,NLNK,1H 2018;,06/30/2018,Phase 2
82.76,LJN452,NVS,1H 2018;,06/30/2018,Phase 2
82.76,LEE011: MONALEESA-3,NVS,2Q 2018;,06/30/2018,Phase 3
80.75,Neratinib plus Kadcyla (T-DM1),PBYI,2Q 2018;,06/30/2018,Phase 1/2
80.75,Neratinib,PBYI,1H 2018;,06/30/2018,Phase 3
4.34,PF708 and Forteo,PFNX,1H 2018;,06/30/2018,Phase 3
35.06,NEOD001 PRONTO,PRTA,2Q 2018;,06/30/2018,Phase 2b
1.46,PLX-PAD (stem cells),PSTI,2Q 2018;,06/30/2018,Phase 2
53.80,KRN23 Burosumab,RARE,1H 2018;,06/30/2018,Phase 2
1.66,Supinoxin,RNN,2Q 2018;,06/30/2018,Phase 2a
26.95,RXDX-105,RXDX,1H 2018;,06/30/2018,Phase 1b
4.30,Samcyprone - RXI-SCP-1502,RXII,1Q/2Q 2018;,06/30/2018,Phase 2
27.28,Setmelanotide,RYTM,1H 2018;,06/30/2018,Phase 2
7.75,COR-003 (levoketoconazole) - SONICS,SBBP,2Q 2018;,06/30/2018,Phase 3
26.35,SB-318,SGMO,1H 2018;,06/30/2018,Phase 1/2
9.83,Entinostat plus Keytruda - ENCORE 601,SNDX,2Q 2018;,06/30/2018,Phase 1/2
12.00,SPR741,SPRO,1H 2018;,06/30/2018,Phase 1b
28.61,TD-9855,TBPH,1H 2018;,06/30/2018,Phase 2a
16.55,TG-1101 and TGR-1202 - UNITY-CLL study,TGTX,2Q 2018;,06/30/2018,Phase 3
12.91,Toca 511 & Toca FC,TOCA,1H 2018;,06/30/2018,Phase 2/3
3.54,TPIV200,TPIV,1H 2018;,06/30/2018,Phase 2
1.00,Ropinirole implant,TTNP,1H 2018;,06/30/2018,Phase 1/2
1.60,VCL-HB01 HSV-2 Therapeutic Vaccine,VICL,2Q 2018;,06/30/2018,Phase 2
176.26,VX-445 in combination with tezacaftor and ivacaftor,VRTX,1H 2018;,06/30/2018,Phase 2
5.80,BTA074 5% topical gel,VXRT,2Q 2018;,06/30/2018,Phase 2
16.01,Dasiglucagon,ZEAL,2Q 2018;,06/30/2018,Phase 3
45.00,ZX008 - Study 1504,ZGNX,Late 2Q 2018;,06/30/2018,Phase 3
52.98,Inotersen (IONIS-TTRRx),IONS,,07/06/2018,PDUFA priority review
1.85,RBP-7000,DRRX,,07/28/2018,PDUFA
7.48,Buprenorphine,INSY,,07/28/2018,PDUFA
133.02,Givosiran,ALNY,Mid-2018;,07/31/2018,Phase 3
125.68,Eculizumab,ALXN,Mid-2018;,07/31/2018,Phase 3
0.98,BL-8040,BLRX,Mid-2018;,07/31/2018,Phase 2
28.03,Marzeptacog alfa,CBIO,July 2018;,07/31/2018,Phase 2
92.56,Lico-cel (CD-19 JCAR017) - TRANSCEND,CELG,2018;,07/31/2018,Phase 1/2
34.10,CX 072,CTMX,Mid-2018;,07/31/2018,Phase 1/2
1.25,Vicinium,EBIO,Mid-2018;,07/31/2018,Phase 3
2.16,AEVI-001 (NFC-1),GNMX,Mid-2018;,07/31/2018,Phase 2
2.16,AEVI-002 (Anti-LIGHT mAb),GNMX,Mid-2018;,07/31/2018,Phase 1/2
37.36,Dezamizumab,GSK,Mid-2018;,07/31/2018,Phase 2b
37.36,Dolutegravir + lamivudine (GEMINI 2),GSK,Mid-2018;,07/31/2018,Phase 3
37.36,Dolutegravir + lamivudine (GEMINI 1),GSK,Mid-2018;,07/31/2018,Phase 3
34.60,Sitravatinib plus nivolumab,MRTX,Mid-2018;,07/31/2018,Phase 2
34.60,Mocetinostat and durvalumab,MRTX,Mid-2018;,07/31/2018,Phase 2
22.40,Tumor Treating Fields (TTFields) STELLAR,NVCR,Mid-2018;,07/31/2018,Phase 2
14.00,OBE2109 - EDELWEISS,OBSV,Mid-2018;,07/31/2018,Phase 2b
1.47,Pulmazole (PUR1900),PULM,Mid-2018;,07/31/2018,Phase 1
6.12,RHB-104 MAP US,RDHL,Mid-2018;,07/31/2018,Phase 3
15.79,SB 9200,SBPH,Mid-2018;,07/31/2018,Phase 2a
1.43,SCY-078 - oral,SCYX,Mid-2018;,07/31/2018,Phase 2b
26.35,SB-525,SGMO,Mid-2018;,07/31/2018,Phase 1/2
26.35,SB-913 - CHAMPIONS,SGMO,Mid-2018;,07/31/2018,Phase 1/2
12.00,SPR994,SPRO,Mid-2018;,07/31/2018,Phase 1
74.36,SRP-5051,SRPT,Mid-2018;,07/31/2018,Phase 1/2
2.80,TRC253,TCON,Mid-2018;,07/31/2018,Phase 1/2
2.80,TRC105 and Inlyta,TCON,Mid-2018;,07/31/2018,Phase 2
43.99,Luspatercept - BELIEVE,XLRN,Mid-2018;,07/31/2018,Phase 3
43.99,Luspatercept - MEDALIST,XLRN,Mid-2018;,07/31/2018,Phase 3
8.00,ZGN-1061,ZFGN,Mid-2018;,07/31/2018,Phase 2
7.76,Remoxy,PTIE,,08/07/2018,PDUFA
5.98,TPOXX,SIGA,,08/08/2018,PDUFA priority review
133.02,Patisiran APOLLO,ALNY,,08/11/2018,PDUFA priority review
341.70,EYLEA,REGN,,08/11/2018,PDUFA
14.91,Migalastat,FOLD,,08/13/2018,PDUFA priority review
83.95,Ivosidenib,AGIO,,08/21/2018,PDUFA priority review
16.45,Stannsoporfin,MNK,,08/22/2018,PDUFA priority review
17.52,INVELTYS,KALA,,08/24/2018,PDUFA
15.38,IDP-121,VRX,,08/26/2018,PDUFA
157.28,ESMYA  (ulipristal acetate),AGN,August 2018;,08/28/2018,PDUFA
2.90,Eravacycline (TP-434) - IGNITE4,TTPH,,08/28/2018,PDUFA priority review
75.26,Bempedoic Acid/ Ezetimibe (1002FDC-053),ESPR,August 2018;,08/31/2018,Phase 3
4.25,Symjepi - low dose,ADMP,,09/03/2018,PDUFA
4.23,ACH-4471,ACHN,3Q 2018;,09/30/2018,Phase 2
4.50,rAAV-hRS1,AGTC,Late-3Q/Early-4Q est;,09/30/2018,Phase 1/2
3.60,Vascepa REDUCE-IT outcomes trial,AMRN,3Q 2018;,09/30/2018,Phase 3
16.55,AQX-1125 LEADERSHIP,AQXP,3Q 2018;,09/30/2018,Phase 3
16.72,KX-01 (KX2-391) Ointment,ATNX,3Q 2018;,09/30/2018,Phase 3
16.72,Oraxol,ATNX,3Q 2018;,09/30/2018,Phase 3
1.64,Nelotanserin,AXON,3Q 2018;,09/30/2018,Phase 2
23.67,AVP-786,CNCE,3Q 2018;,09/30/2018,Phase 3
9.75,Exendin 9-39,EIGR,3Q 2018;,09/30/2018,Phase 2
75.26,Bempedoic acid - CLEAR LDL-C Lowering Program 1002-047,ESPR,September 2018;,09/30/2018,Phase 3
0.57,EGP-437,EYEG,3Q 2018;,09/30/2018,Phase 3
26.73,Zilretta - FX006,FLXN,3Q 2018;,09/30/2018,Phase 3
5.72,FMX103,FOMX,Late 3Q or early 4Q 2018;,09/30/2018,Phase 3
5.72,FMX101 - FX2017-22,FOMX,3Q 2018;,09/30/2018,Phase 3
80.72,GS-5734,GILD,3Q 2018;,09/30/2018,Phase 2
2.86,NeoCart,HSGX,3Q 2018;,09/30/2018,Phase 3
4.27,Ganaxolone,MRNS,3Q 2018;,09/30/2018,Phase 2
50.87,Concizumab - explorer,NVO,3Q 2018;,09/30/2018,Phase 2
50.87,Somapacitan (NN8640) - REAL 3,NVO,3Q 2018;,09/30/2018,Phase 3
82.76,INC280,NVS,3Q 2018;,09/30/2018,Phase 2
8.10,1404,PGNX,3Q 2018;,09/30/2018,Phase 3
13.20,Ezutromid,SMMT,3Q 2018;,09/30/2018,Phase 2
19.90,SNA-125,SNNA,3Q 2018;,09/30/2018,Phase 1/2
3.58,TNX-102 SL,TNXP,3Q 2018;,09/30/2018,Phase 3
57.07,MitoGel - OLYMPUS,URGN,3Q 2018;,09/30/2018,Phase 3
5.90,VTI-308,VTL,3Q 2018;,09/30/2018,Phase 3
25.65,INBRIJA (CVT-301),ACOR,,10/05/2018,PDUFA
79.61,"Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN",LLY,,10/10/2018,PDUFA
15.38,IDP-122,VRX,,10/15/2018,PDUFA
14.40,Sarecycline,PRTK,4Q 2018;,10/19/2018,PDUFA
341.70,Dupixent (dupilumab) - LIBERTY ASTHMA QUEST,REGN,,10/20/2018,PDUFA
55.14,Doravirine (MK-1439),MRK,,10/23/2018,PDUFA
5.47,TX-001HR,TXMD,,10/28/2018,PDUFA
58.49,ALKS 3831 - ENLIGHTEN-2,ALKS,Fall 2018;,10/31/2018,Phase 3
4.24,SNS-062,SNSS,Fall 2018;,10/31/2018,Phase 1/2
1.98,Oliceridine (TRV130),TRVN,,11/02/2018,PDUFA
82.76,Adalimumab,NVS,"Nov 16, 2018 est only;",11/16/2018,PDUFA
28.61,Revefenacin,TBPH,,11/30/2018,PDUFA
83.95,Ivosidenib or enasidenib,AGIO,ASH 2018;,12/01/2018,Phase 1
231.95,LentiGlobin - HGB-212,BLUE,ASH 2018;,12/05/2018,Phase 3
231.95,LentiGlobin - HGB-206,BLUE,ASH 2018;,12/05/2018,Phase 1/2
152.43,JZP-110,JAZZ,,12/20/2018,PDUFA
119.29,ABT-494 - SELECT-COMPARE,ABBV,2018;,12/31/2018,Phase 3
119.29,Imbruvica - PHOENIX,ABBV,2018;,12/31/2018,Phase 3
54.16,ALX-0171,ABLX,2H 2018;,12/31/2018,Phase 2b
5.80,"ARB-1467, tenofovir, and pegylated interferon",ABUS,2H 2018;,12/31/2018,Phase 2
25.33,Pimavanserin - CLARITY,ACAD,2H 2018;,12/31/2018,Phase 2
4.23,ACH-4471,ACHN,4Q 2018;,12/31/2018,Phase 2
12.09,ACI-24 (anti-Abeta vaccine),ACIU,2018;,12/31/2018,Phase 1/2
21.28,ATI-50002 - dose ranging,ACRS,YE 2018;,12/31/2018,Phase 2
6.70,ADVM-043,ADVM,2H 2018;,12/31/2018,Phase 1/2
157.28,ABICIPAR,AGN,2H 2018;,12/31/2018,Phase 3
33.63,AR101 RAMSES,AIMT,2H 2018;,12/31/2018,Phase 3
14.08,Vadadustat - FO2RWARD,AKBA,Late 2018/Early 2019;,12/31/2018,Phase 2
19.44,AKCEA-ANGPTL3-LRx,AKCA,2018;,12/31/2018,Phase 2
19.44,AKCEA-APO(a)-LRx,AKCA,2H 2018;,12/31/2018,Phase 2b
8.80,ADX-102,ALDX,2H 2018;,12/31/2018,Phase 2b
8.80,ADX-102,ALDX,2H 2018;,12/31/2018,Phase 2b
8.80,ADX-102,ALDX,2H 2018;,12/31/2018,Phase 3
8.80,ADX-102,ALDX,2H 2018;,12/31/2018,Phase 2
7.09,ALLN-177,ALNA,2H 2018;,12/31/2018,Phase 2
133.02,ALN-CC5 (cemdisiran),ALNY,2018;,12/31/2018,Phase 1/2
125.68,ALXN1210,ALXN,4Q 2018;,12/31/2018,Phase 3
125.68,ALXN1210,ALXN,2Q 2018;,12/31/2018,Phase 3
191.10,ABP 710,AMGN,2H 2018;,12/31/2018,Phase 3
53.49,Cingal,ANIK,2018;,12/31/2018,Phase 3
22.26,APL-2 subcutaneous,APLS,2H 2018;,12/31/2018,Phase 2
78.60,ARGX-113,ARGX,2H 2018;,12/31/2018,Phase 2
78.60,ARGX-110,ARGX,YE 2018;,12/31/2018,Phase 1/2
78.60,ARGX-113,ARGX,YE 2018;,12/31/2018,Phase 2
47.80,AM0010 (PEG-IL-10) and Pembrolizumab - Cypress 1,ARMO,YE 2018;,12/31/2018,Phase 2b
47.80,AM0010 (PEG-IL-10) and Nivolumab - Cypress 2,ARMO,YE 2018;,12/31/2018,Phase 2b
1.80,Miransertib - ARQ 092,ARQL,2018;,12/31/2018,Phase 1b
1.90,AST-VAC2,AST,2H 2018;,12/31/2018,Phase 1/2
0.43,Actimab-M,ATNM,2H 2018;,12/31/2018,Phase 1
0.43,Actimab-A,ATNM,2H 2018;,12/31/2018,Phase 2
5.54,Voclosporin,AUPH,2H 2018;,12/31/2018,Phase 2
5.54,Voclosporin,AUPH,2H 2018;,12/31/2018,Phase 2
2.80,AXS-05 ADVANCE-1,AXSM,2H 2018;,12/31/2018,Phase 2/3
33.79,Lynparza,AZN,2H 2018;,12/31/2018,Phase 3
33.79,Farxiga - DECLARE,AZN,2H 2018;,12/31/2018,Phase 3
33.79,FASENRA (benralizumab) - TERRANOVA,AZN,2H 2018;,12/31/2018,Phase 3
33.79,Durvalumab +/- tremelimumab (NEPTUNE),AZN,2H 2018;,12/31/2018,Phase 3
33.79,Anifrolumab,AZN,2H 2018;,12/31/2018,Phase 3
2.93,MS1819,AZRX,4Q 2018;,12/31/2018,Phase 2
2.93,MS1819-SD,AZRX,2H 2018;,12/31/2018,Phase 2
5.58,BCX7353 - ZENITH-1,BCRX,2H 2018;,12/31/2018,Phase 2
286.10,Raxatrigine - BIIB074 (Nav1.7 inhibitor),BIIB,2018;,12/31/2018,Phase 2
286.10,BAN2401 (Aβ mAb),BIIB,2H 2018;,12/31/2018,Phase 2
104.98,BIVV001 (EXTEN-A),BIVV,2018;,12/31/2018,Phase 1/2
1.85,INOpulse delivery device,BLPH,YE 2018;,12/31/2018,Phase 2b
1.85,INOpulse delivery device,BLPH,YE 2018;,12/31/2018,Phase 2
1.85,INOpulse delivery device,BLPH,2018;,12/31/2018,Phase 3
0.98,BL-8040 in combination with TECENTRIQ (atezolizumab),BLRX,2H 2018;,12/31/2018,Phase 1/2
0.98,BL-8040 in combination with KEYTRUDA - COMBAT trial,BLRX,2H 2018;,12/31/2018,Phase 2
0.98,BL-8040,BLRX,2018;,12/31/2018,Phase 2b
0.98,BL-8040 GENESIS,BLRX,2H 2018;,12/31/2018,Phase 3
67.92,CM-602 – Opdivo + Elo + SOC,BMY,2H 2018;,12/31/2018,Phase 3
67.92,CM-459 – Opdivo,BMY,2H 2018;,12/31/2018,Phase 3
67.92,CM-451 – Opdivo + Yervoy,BMY,2H 2018;,12/31/2018,Phase 3
28.00,Plinabulin,BYSI,2018;,12/31/2018,Phase 3
8.10,CB-839 with paclitaxel,CALA,4Q 2018;,12/31/2018,Phase 2
1.56,Namodenoson (CF102),CANF,2H 2018;,12/31/2018,Phase 2
10.02,Tucatinib - MOUNTAINEER,CASC,2018;,12/31/2018,Phase 2
92.56,JCARH125,CELG,2018;,12/31/2018,Phase 1
92.56,OTEZLA - SPSO-001,CELG,2018;,12/31/2018,Phase 3
92.56,REVLIMID - ROBUST,CELG,2018;,12/31/2018,Phase 3
92.56,Oral Azacitidine - CC-486-AML-001,CELG,2H 2018;,12/31/2018,Phase 3
92.56,ABRAXANE - PANC-003 apact,CELG,2018;,12/31/2018,Phase 3
92.56,ABRAXANE - IMpower 130 ( I/O Combo),CELG,2018;,12/31/2018,Phase 3
92.56,ABRAXANE - IMpower 131 ( I/O Combo),CELG,2018;,12/31/2018,Phase 3
92.56,ABRAXANE - IMPassion ( I/O Combo),CELG,2018;,12/31/2018,Phase 3
2.09,CF-301,CFRX,4Q 2018;,12/31/2018,Phase 2
13.00,Suprachoroidal CLS-TA - SAPPHIRE,CLSD,4Q 2018;,12/31/2018,Phase 3
5.69,IV Brincidofovir,CMRX,2H 2018;,12/31/2018,Phase 2
10.00,CX-2009 - PROCLAIM,CMTX,2H 2018;,12/31/2018,Phase 2
7.27,Emricasan,CNAT,2H 2018;,12/31/2018,Phase 2
23.67,CTP-543,CNCE,4Q 2018;,12/31/2018,Phase 2a
34.10,CX 2009,CTMX,2H 2018;,12/31/2018,Phase 1/2
8.30,CK-2127107 - FORTITUDE-ALS,CYTK,2H 2018;,12/31/2018,Phase 2
8.30,CK-2127107,CYTK,2H 2018;,12/31/2018,Phase 2
24.54,DCC-3014,DCPH,2H 2018;,12/31/2018,Phase 1
14.12,DCR-PHXC,DRNA,2H 2018;,12/31/2018,Phase 1
1.85,DUR-928,DRRX,2018;,12/31/2018,Phase 2
57.66,Fulvestrant,EGRX,4Q 2018;,12/31/2018,Phase 3
9.75,Ubenimex - ULTRA,EIGR,2H 2018;,12/31/2018,Phase 2
18.10,Tazemetostat,EPZM,2018;,12/31/2018,Phase 2
55.45,Roxadustat - ANDES,FGEN,4Q 2018;,12/31/2018,Phase 3
5.07,FLX-787,FLKS,2018;,12/31/2018,Phase 2
26.73,Zilretta - SHIP,FLXN,2H 2018;,12/31/2018,Phase 2
7.71,Gemcabene - AZURE-1,GEMP,2H 2018;,12/31/2018,Phase 2
80.72,Tirabrutinib (GS-4059),GILD,4Q 2018;,12/31/2018,Phase 2
80.72,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2),GILD,2H 2018;,12/31/2018,Phase 2
103.18,Filgotinib - FINCH 2,GLPG,2018;,12/31/2018,Phase 3
17.83,GMI-1070 (rivipansel),GLYC,2H 2018;,12/31/2018,Phase 3
37.36,Dolutegravir + rilpivirine,GSK,2H 2018;,12/31/2018,Phase 3
34.23,Trilaciclib,GTHX,4Q 2018;,12/31/2018,Phase 2
34.23,Trilaciclib,GTHX,4Q 2018;,12/31/2018,Phase 2
34.23,Trilaciclib plus Tecentriq,GTHX,4Q 2018;,12/31/2018,Phase 2
21.50,Enobosarm,GTXI,2H 2018;,12/31/2018,Phase 2
117.04,Epidiolex,GWPH,2H 2018;,12/31/2018,Phase 3
117.04,Epidiolex,GWPH,2H 2018;,12/31/2018,Phase 3
20.62,PEGPH20 in combination with KEYTRUDA,HALO,2H 2018;,12/31/2018,Phase 1b
11.24,Kadcyla (KATHERINE).,IMGN,2018;,12/31/2018,Phase 3
11.35,IMM-124E,IMRN,4Q 2018;,12/31/2018,Phase 2
11.35,IMM-529,IMRN,4Q 2018;,12/31/2018,Phase 1/2
94.23,INCB54828 (FIGHT-202),INCY,2018;,12/31/2018,Phase 2
7.48,Cannabidiol,INSY,YE 2018;,12/31/2018,Phase 2
23.39,ITI-007 - Monotherapy (Study 401),ITCI,2H 2018;,12/31/2018,Phase 3
23.39,ITI-007-201,ITCI,2H 2018;,12/31/2018,Phase 3
133.80,STELARA (USTEKINUMAB),JNJ,2018;,12/31/2018,Phase 3
16.86,Selinexor - SADAL,KPTI,2H 2018;,12/31/2018,Phase 2b
79.61,Ramucirumab,LLY,2018;,12/31/2018,Phase 3
79.61,Ramucirumab,LLY,2018;,12/31/2018,Phase 3
79.61,Empagliflozin,LLY,2018;,12/31/2018,Phase 3
79.61,Ixekizumab,LLY,2018;,12/31/2018,Phase 3
79.61,Tradjenta (linagliptin) - CARMELINA CV outcomes,LLY,2018;,12/31/2018,–
79.61,Ultra rapid insulin,LLY,2018;,12/31/2018,Phase 3
79.61,Tanezumab,LLY,2018;,12/31/2018,Phase 3
79.61,Ramucirumab,LLY,2018;,12/31/2018,Phase 3
79.61,Flortaucipir F 18 (Tau imaging agent),LLY,2018;,12/31/2018,Phase 3
7.22,DKN-01 and Paclitaxel,LPTX,2018;,12/31/2018,Phase 2
7.22,TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo,LPTX,2018;,12/31/2018,Phase 1
7.22,DKN-01 + KEYTRUDA,LPTX,2018;,12/31/2018,Phase 1/2
11.58,MM-121 (SHERBOC),MACK,2H 2018;,12/31/2018,Phase 2
11.58,MM-121,MACK,2H 2018;,12/31/2018,Phase 2
2.14,Annamycin,MBRX,2018;,12/31/2018,Phase 1/2
30.58,Flotetuzumab,MGNX,2018;,12/31/2018,Phase 1
33.00,Serlopitant,MNLO,Late 2018 or early 2019;,12/31/2018,Phase 2
33.00,Serlopitant,MNLO,Late 2018 or early 2019;,12/31/2018,Phase 2
4.27,Ganaxolone - oral,MRNS,4Q 2018;,12/31/2018,Phase 2
4.27,Ganaxolone,MRNS,4Q 2018;,12/31/2018,Phase 2
53.05,MYK-491,MYOK,2H 2018;,12/31/2018,Phase 1b
92.43,INGREZZA - T-Force GOLD,NBIX,Late-2018;,12/31/2018,Phase 2b
19.49,NUC-3373,NCNA,2018;,12/31/2018,Phase 1
19.49,NUC-1031 (Acelarin),NCNA,2018;,12/31/2018,Phase 2
13.15,NSR-RPGR,NITE,2018;,12/31/2018,Phase 1/2
108.34,NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL),NKTR,2H 2018;,12/31/2018,Phase 1/2
2.06,RSV vaccine - prepare trial,NVAX,4Q 2018 or 1Q 2019;,12/31/2018,Phase 3
50.87,Semaglutide - oral - PIONEER,NVO,2018;,12/31/2018,Phase 3
82.76,BYL719,NVS,2H 2018;,12/31/2018,Phase 3
82.76,LIK066,NVS,2H 2018;,12/31/2018,Phase 2
82.76,Entresto - PARAGON,NVS,2H 2018;,12/31/2018,Phase 3
14.00,OBE022 - PROLONG,OBSV,YE 2018;,12/31/2018,Phase 2a
14.00,Nolasiban (OBE001) - IMPLANT2,OBSV,4Q 2018;,12/31/2018,Phase 3
5.90,OTX-TP,OCUL,4Q 2018;,12/31/2018,Phase 3
2.01,ImmunoPulse IL-12 - PISCES,ONCS,2018;,12/31/2018,Phase 2b
1.07,Oral Rigosertib and azacitidine,ONTX,2018;,12/31/2018,Phase 2
2.99,Zimura,OPHT,YE 2018;,12/31/2018,Phase 2a
8.49,OV101 (STARS),OVID,2H 2018;,12/31/2018,Phase 2
80.75,Neratinib SUMMIT,PBYI,2H 2018;,12/31/2018,Phase 2
80.75,Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL,PBYI,4Q 2018;,12/31/2018,Phase 2
7.27,PRS-343,PIRS,2H 2018;,12/31/2018,Phase 1/2
7.27,PRS-060,PIRS,4Q 2018;,12/31/2018,Phase 1
7.27,PRS-080,PIRS,2H 2018;,12/31/2018,Phase 2a
3.40,QR-313,PRQR,2018;,12/31/2018,Phase 1/2
3.40,QR-010,PRQR,2018;,12/31/2018,Phase 1/2
1.47,PUR1800,PULM,4Q 2018;,12/31/2018,Phase 2a
25.51,AMT-061,QURE,YE 2018;,12/31/2018,Phase 3
53.80,KRN23 Burosumab,RARE,2H 2018;,12/31/2018,Phase 3
53.80,DTX301,RARE,2H 2018;,12/31/2018,Phase 1/2
53.80,UX007 (triheptanoin),RARE,2H 2018;,12/31/2018,Phase 3
6.12,RHB-105 - ERADICATE Hp 2,RDHL,2H 2018;,12/31/2018,Phase 3
341.70,Cemiplimab,REGN,2H 2018;,12/31/2018,Phase 2
341.70,Dupixent (dupilumab),REGN,4Q 2018;,12/31/2018,Phase 3
22.15,Bardoxolone - PHOENIX,RETA,2H 2018;,12/31/2018,Phase 2
22.15,Bardoxolone methyl - CATALYST,RETA,2H 2018;,12/31/2018,Phase 3
36.00,RGX-314,RGNX,Late 2018;,12/31/2018,Phase 1
36.00,RGX-501,RGNX,Late 2018;,12/31/2018,Phase 1/2
32.75,"RT002 - SAKURA 1, 2 and 3",RVNC,2H 2018;,12/31/2018,Phase 3
177.75,SAGE-217,SAGE,4Q 2018;,12/31/2018,Phase 2
7.75,COR-003 (levoketoconazole) - LOGICS,SBBP,4Q 2018;,12/31/2018,Phase 3
15.79,Inarigivir and Vemlidy,SBPH,2H 2018;,12/31/2018,Phase 2
1.43,SCY-078 - oral - CARES,SCYX,4Q 2018;,12/31/2018,Phase 3
1.43,SCY-078 - oral (FURI),SCYX,4Q 2018;,12/31/2018,Phase 3
57.19,ADCETRIS in combination with chemotherapy - ECHELON-2,SGEN,2018;,12/31/2018,Phase 3
26.35,SB-FIX,SGMO,2018;,12/31/2018,Phase 1/2
9.83,Entinostat plus Tecentriq - ENCORE 602,SNDX,2H 2018;,12/31/2018,Phase 2
2.04,SGX301 (synthetic hypericin),SNGX,2H 2018;,12/31/2018,Phase 3
19.90,SNA-001,SNNA,2H 2018;,12/31/2018,Phase 3
19.90,SNA-001,SNNA,2H 2018;,12/31/2018,Phase 3
40.39,Isatuximab,SNY,4Q 2018;,12/31/2018,Phase 3
18.67,SPI-2012 (ROLONTIS),SPPI,2H 2018;,12/31/2018,Phase 3
74.36,Microdystrophin gene therapy rAAVrh74.MCK.GALGT2,SRPT,2H 2018;,12/31/2018,Phase 1/2
74.36,GALGT2 gene therapy,SRPT,2H 2018;,12/31/2018,Phase 1/2
2.47,SRA737,SRRA,4Q 2018;,12/31/2018,Phase 1/2
11.26,SYNB1618,SYBX,2H 2018;,12/31/2018,Phase 1
11.26,SYNB1020,SYBX,YE 2018;,12/31/2018,Phase 1/2
28.61,Closed Triple - CAPTAIN,TBPH,2018;,12/31/2018,Phase 3
2.80,TRC105 + Opdivo,TCON,2H 2018;,12/31/2018,Phase 1/2
2.80,TRC105,TCON,2018;,12/31/2018,Phase 2
2.80,TRC102,TCON,2018;,12/31/2018,Phase 2
2.80,TRC105 (TAPPAS),TCON,2H 2018;,12/31/2018,Phase 3
15.90,RTB101 and Everolimus,TORC,2H 2018;,12/31/2018,Phase 2b
68.12,Niraparib - AVANOVA,TSRO,2H 2018;,12/31/2018,Phase 1/2
2.68,SM-88,TYME,2H 2018;,12/31/2018,Phase 2
115.34,Esuberaprost - BEAT,UTHR,2018;,12/31/2018,Phase 3
115.34,Orenitram,UTHR,2H 2018;,12/31/2018,Phase 3
5.80,VK2809,VKTX,2H 2018;,12/31/2018,Phase 2
19.90,Tradipitant,VNDA,YE 2018;,12/31/2018,Phase 2
19.90,HETLIOZ (tasimelteon),VNDA,YE 2018;,12/31/2018,Phase 3
1.30,AV-101,VTGN,2H 2018;,12/31/2018,Phase 2
4.72,XBIO-101,XBIT,YE 2018;,12/31/2018,Phase 2
43.99,ACE-083,XLRN,2H 2018;,12/31/2018,Phase 2
32.72,XmAb5871,XNCR,4Q 2018;,12/31/2018,Phase 2
16.01,Dasiglucagon,ZEAL,2H 2018;,12/31/2018,Phase 3
116.87,ANB020,ANAB,,02/17/2019,Phase 2a
0.96,CaPre,ACST,Early 2019;,02/28/2019,Phase 3
176.26,VX-150,VRTX,Early 2019;,02/28/2019,Phase 2
33.63,AR101 ARTEMIS,AIMT,Early 2019;,03/31/2019,Phase 3
67.84,TransCon,ASND,1Q 2019;,03/31/2019,Phase 3
5.55,CLBS03,CLBS,Early 2019;,03/31/2019,Phase 2
2.64,ThermoDox - OPTIMA,CLSN,1Q 2019;,03/31/2019,Phase 3
3.22,Mino-Lok,CTXR,Early 2019;,03/31/2019,Phase 3
6.89,Amphora - AMPOWER,EVFM,1Q 2019;,03/31/2019,Phase 3
5.07,FLX-787 - COMMEND US trial,FLKS,Early 2019;,03/31/2019,Phase 2
5.07,FLX-787 COMMIT,FLKS,Early 2019;,03/31/2019,Phase 2
17.83,GMI-1271,GLYC,Early 2019;,03/31/2019,–
37.36,Danirixin,GSK,1Q 2019;,03/31/2019,Phase 2b
20.62,PEGPH20 - HALO-301,HALO,1Q 2019;,03/31/2019,Phase 3
11.35,IMM-529,IMRN,1Q 2019;,03/31/2019,Phase 1/2
7.19,ORMD-0801,ORMP,Early 2019;,03/31/2019,Phase 2b
2.30,Vonapanitase (PRT-201) PATENCY-2,PRTO,March 2019;,03/31/2019,Phase 3
1.66,RX-3117 in combination with Abraxane,RNN,1Q 2019;,03/31/2019,Phase 2a
25.85,CNSA-001,RTRX,Early 2019;,03/31/2019,Phase 2
44.85,SPN-812,SUPN,1Q 2019;,03/31/2019,Phase 3
44.85,SPN-810,SUPN,1Q 2019;,03/31/2019,Phase 3
44.15,ATA188,ATRA,1H 2019;,06/30/2019,Phase 1
44.15,ATA 129 - ALLELE,ATRA,1H 2019;,06/30/2019,Phase 3
67.92,CM-714 Opdivo + Yervoy,BMY,1H 2019;,06/30/2019,Phase 3
67.92,CM-568 - Opdivo + Yervoy,BMY,2H 2018 – 1H 2019;,06/30/2019,Phase 2
1.56,Namodenoson (CF102),CANF,1H 2019;,06/30/2019,Phase 2
5.69,Oral Brincidofovir,CMRX,1H 2019;,06/30/2019,–
7.27,Emricasan,CNAT,1H 2019;,06/30/2019,Phase 2
9.43,Lebrikizumab,DERM,1H 2019;,06/30/2019,Phase 2b
4.95,CEVA101,FBIO,1H 2019;,06/30/2019,Phase 2
57.15,GBT440 - HOPE,GBT,1H 2019;,06/30/2019,Phase 3
80.72,GS-9877,GILD,1H 2019;,06/30/2019,Phase 2
80.72,F/TAF (Descovy),GILD,2Q 2019;,06/30/2019,Phase 3
1.24,GEN-009,GNCA,1H 2019;,06/30/2019,Phase 1/2
37.36,Tapinarof (GSK2894512),GSK,1H 2019;,06/30/2019,Phase 3
37.36,Inhaled PI3Kδ inhibitor (Nemiralisib),GSK,1H 2019;,06/30/2019,Phase 2b
64.07,Ocaliva (Obeticholic acid (OCA)) - REGENERATE,ICPT,1H 2019;,06/30/2019,Phase 3
5.75,MIN-101,NERV,1H 2019;,06/30/2019,Phase 3
1.07,IV Rigosertib - INSPIRE,ONTX,1H 2019;,06/30/2019,Phase 3
7.45,RA101495,RARX,1H 2019;,06/30/2019,Phase 2
27.28,Setmelanotide,RYTM,1H 2019;,06/30/2019,Phase 3
28.19,SGT-001,SLDB,1H 2019;,06/30/2019,Phase 1/2
9.83,Entinostat plus Tecentriq - ENCORE 603,SNDX,1H 2019;,06/30/2019,Phase 1/2
2.04,SGX942 (dusquetide),SNGX,1H 2019;,06/30/2019,Phase 3
19.90,SNA-120,SNNA,1H 2019;,06/30/2019,Phase 2b
10.98,Molgradex - IMPALA,SVRA,2Q 2019;,06/30/2019,Phase 3
16.55,TG-1101 and TGR-1202 - UNITY-NHL study,TGTX,1H 2019;,06/30/2019,Phase 2/3
1.30,AV-101,VTGN,1H 2019;,06/30/2019,Phase 2
34.36,Inclisiran - ORION-10,MDCO,3Q 2019;,09/30/2019,Phase 3
34.36,Inclisiran - ORION 11,MDCO,3Q 2019;,09/30/2019,–
34.36,Inclisiran - ORION-9,MDCO,3Q 2019;,09/30/2019,Phase 3
22.15,Bardoxolone methyl - CARDINAL,RETA,3Q 2019;,09/30/2019,Phase 3
119.29,Venetoclax,ABBV,2019;,12/31/2019,Phase 3
4.23,ACH-4471,ACHN,2019;,12/31/2019,Phase 2
2.20,Axalimogene filolisbac + durvalumab,ADXS,2019;,12/31/2019,Phase 1/2
2.30,AFM13,AFMD,2019;,12/31/2019,Phase 2
157.28,RAPASTINEL,AGN,2019;,12/31/2019,Phase 3
14.08,Vadadustat - INNO2VATE,AKBA,2019;,12/31/2019,Phase 3
14.08,Vadadustat - PRO2TECT,AKBA,2019;,12/31/2019,Phase 3
19.44,AKCEA-ANGPTL3-LRx,AKCA,2019;,12/31/2019,Phase 2
19.44,AKCEA-APOCIII-LRx,AKCA,2019;,12/31/2019,Phase 2b
7.09,ALLN-177 (URIROX-1),ALNA,2H 2019;,12/31/2019,Phase 3
191.10,KYPROLIS (ARROW),AMGN,2019;,12/31/2019,Phase 3
0.43,Iomab-B,ATNM,2H 2019;,12/31/2019,Phase 3
33.79,Imfinzi + tremelimumab  (POSEIDON),AZN,2019;,12/31/2019,Phase 3
33.79,Imfinzi + tremelimumab (CASPIAN),AZN,2019;,12/31/2019,Phase 3
33.79,Imfinzi + tremelimumab  (DANUBE),AZN,2019;,12/31/2019,Phase 3
33.79,Lynparza - SOLO 3,AZN,2019;,12/31/2019,Phase 3
33.79,Farxiga (Dapa-HF),AZN,2019;,12/31/2019,Phase 3
33.79,Lanabecestat (AZD3293) - AMARANTH,AZN,2019;,12/31/2019,Phase 3
33.79,Durvalumab +/- tremelimumab (DANUBE),AZN,2019;,12/31/2019,Phase 3
33.79,Brilinta (THEMIS),AZN,2019;,12/31/2019,Phase 3
3.41,NurOwn,BCLI,Late 2019;,12/31/2019,Phase 3
83.81,Vosoritide,BMRN,2H 2019;,12/31/2019,Phase 3
67.92,CM-649 – Opdivo+ Yervoy or Chemo,BMY,2019;,12/31/2019,Phase 3
67.92,CM-9LA Opdivo + Yervoy + Chemo,BMY,2H 2019;,12/31/2019,Phase 3
67.92,CM-651 – Opdivo + Yervoy,BMY,2019;,12/31/2019,Phase 3
92.56,REVLIMID - MAGNIFY NHL-010,CELG,2019;,12/31/2019,Phase 3
1.60,Mycapssa - OPTIMAL,CHMA,2019;,12/31/2019,Phase 3
7.27,Emricasan,CNAT,2H 2019;,12/31/2019,Phase 2b
24.54,DCC-2618 - INVICTUS,DCPH,2019;,12/31/2019,Phase 3
8.20,Lu-PSMA-617,ECYT,2H 2019;,12/31/2019,Phase 3
80.72,GS-9876,GILD,2H 2019;,12/31/2019,Phase 2
37.36,Mepolizumab - SYNAPSE,GSK,2019;,12/31/2019,Phase 3
11.24,Kadcyla (KAITLIN),IMGN,2019;,12/31/2019,Phase 3
1.83,Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC),IMMP,2019;,12/31/2019,Phase 2b
11.35,IMM-124E,IMRN,2019;,12/31/2019,Phase 2
94.23,Ruxolitinib - REACH 3,INCY,2019;,12/31/2019,Phase 3
94.23,Ruxolitinib - REACH 2,INCY,2019;,12/31/2019,Phase 3
23.39,ITI-007 - Monotherapy (Study 404),ITCI,2019;,12/31/2019,Phase 3
133.80,INVOKANA - CREDENCE,JNJ,2019;,12/31/2019,Phase 3
133.80,DARZALEX (Daratumumab),JNJ,2019;,12/31/2019,Phase 3
10.36,KVD001,KALV,2H 2019;,12/31/2019,Phase 2
5.20,Alpha-1 antitrypsin (AAT),KMDA,2H 2019;,12/31/2019,Phase 1/2
5.20,Alpha-1 antitrypsin (AAT),KMDA,2H 2019;,12/31/2019,Phase 2
16.86,Selinexor - SEAL,KPTI,2019;,12/31/2019,Phase 2/3
16.86,Selinexor - BOSTON,KPTI,2019;,12/31/2019,Phase 3
8.57,Sotagliflozin,LXRX,2019;,12/31/2019,Phase 3
82.76,QVM149,NVS,2019;,12/31/2019,Phase 3
82.76,QAW039 (fevipiprant),NVS,2019;,12/31/2019,Phase 3
82.76,OMB157 (ofatumumab),NVS,2019;,12/31/2019,Phase 3
82.76,Entresto - PARADISE,NVS,2019;,12/31/2019,Phase 3
14.00,OBE2109 - PRIMROSE 2,OBSV,2H 2019;,12/31/2019,Phase 3
14.00,OBE2109 - PRIMROSE,OBSV,2H 2019;,12/31/2019,Phase 3
2.99,Zimura,OPHT,2H 2019;,12/31/2019,Phase 2a
1.02,OvaPrime,OVAS,2019;,12/31/2019,Phase 1/2
3.40,QR-421a,PRQR,2019;,12/31/2019,Phase 1/2
35.06,NEOD001 VITAL,PRTA,2H 2019;,12/31/2019,Phase 3
341.70,Cemiplimab,REGN,2019;,12/31/2019,Phase 2
22.15,Omaveloxolone - MOXIe,RETA,2H 2019;,12/31/2019,Phase 2
11.12,TWIN,SLGL,2019;,12/31/2019,Phase 2
11.12,VERED,SLGL,2019;,12/31/2019,Phase 2
5.20,NeuVax in combination with Herceptin,SLS,4Q 2019;,12/31/2019,Phase 2
40.39,NeoGAA - COMET,SNY,2019;,12/31/2019,Phase 3
40.39,Olipudase alfa,SNY,2019;,12/31/2019,Phase 2/3
4.06,Sci-B-Vac - PROTECT,VBIV,2H 2019;,12/31/2019,Phase 3
9.14,ZYN002,ZYNE,2019;,12/31/2019,Phase 2/3
14.08,Vadadustat - TRILO2GY,AKBA,Early 2020;,02/29/2020,Phase 3
2.20,Axalimogene filolisbac - AIM2CERV Trial,ADXS,2020/21;,06/30/2020,Phase 3
37.36,GSK 165,GSK,1H 2020;,06/30/2020,Phase 2b
16.45,Terlipressin,MNK,1H 2020;,06/30/2020,Phase 3
16.45,H.P. Acthar Gel,MNK,1H 2020;,06/30/2020,Phase 2
16.45,UVADEX (methoxsalen) and Therakos,MNK,1H 2020;,06/30/2020,Phase 3
33.00,Serlopitant,MNLO,1H 2020;,06/30/2020,Phase 3
157.28,RELAMORELIN,AGN,2020;,12/31/2020,Phase 3
33.79,Farxiga (Dapa-CKD),AZN,2020;,12/31/2020,Phase 3
33.79,Durvalumab (ADJUVANT),AZN,2020;,12/31/2020,Phase 3
286.10,Aducanumab (Aβ mAb) - EMERGE,BIIB,2020;,12/31/2020,Phase 3
286.10,Aducanumab (Aβ mAb) - ENGAGE,BIIB,2020;,12/31/2020,Phase 3
2.05,Edasalonexent (CAT-1004),CATB,2020;,12/31/2020,Phase 3
92.56,REVLIMID - MAGNIFY NHL-008,CELG,2020;,12/31/2020,Phase 3
1.60,Mycapssa - MPOWERED,CHMA,2020;,12/31/2020,Phase 3
7.10,Anabasum (Resunab),CRBP,2020;,12/31/2020,Phase 3
17.83,GMI-1271,GLYC,2020;,12/31/2020,Phase 1/2
37.36,Daprodustat - ASCEND-D,GSK,2H 2020;,12/31/2020,Phase 3
5.96,GDC-0084,KZIA,2020;,12/31/2020,Phase 2
22.40,Tumor Treating Fields (TTFields) METIS,NVCR,2020;,12/31/2020,Phase 3
28.71,Tesetaxel - CONTESSA,ODT,2020;,12/31/2020,Phase 3
2.99,Zimura,OPHT,2020;,12/31/2020,Phase 2b
40.39,Efpeglenatide,SNY,2020;,12/31/2020,Phase 3
22.40,Tumor Treating Fields (TTFields) LUNAR,NVCR,2021;,12/31/2021,Phase 3
341.70,Cemiplimab,REGN,2021;,12/31/2021,Phase 3
341.70,Dupixent (dupilumab),REGN,2021;,12/31/2021,Phase 3
11.12,SIRS-T,SLGL,2021;,12/31/2021,Phase 2
22.40,Tumor Treating Fields (TTFields) -  PANOVA 3,NVCR,2022;,12/31/2022,Phase 3
82.76,Cosentyx (secukinumab) - SURPASS,NVS,2022;,12/31/2022,Phase 3
82.76,CNP 520,NVS,2024;,12/31/2024,Phase 2/3
